Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.96 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL29846325 | 1.00 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL147362 | 1.00 | OPRD1 (0.96) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL40902 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL31298106 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6238952 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29461927 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29245643 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8378216 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7532547 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL1314201 | 0.99 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250073226-A1 | USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERS | OSAKA UNIVERSTIY (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4454649-A1 | USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERS | OSAKA UNIVERSITY (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-118434419-A | Use of opioids for the treatment of autism spectrum disorders | 国立大学法人大阪大学 | 2024-08-02 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023120551-A1 | USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERS | 国立大学法人大阪大学 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023028519-A2 | METHODS OF TREATING SUBSTANCE USE DISORDER | ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-113307760-A | Novel crystal of salt of 3-azabicyclo [3.1.0] hexane derivative and medical application thereof | 宇部兴产株式会社 | 2021-08-27 | — | — | CN | disclosed |
| US-20210205172-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | REGIMEN KIT INC (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3838246-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | Regimen Kit, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| EP-3072884-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2529739-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR BILIARY DISEASES | TORAY INDUSTRIES (JP) | 2016-07-13 | — | — | EP | disclosed |
| CN-105764888-A | Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes | 株式会社三和化学研究所 | 2016-07-13 | — | — | CN | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| CN-105377303-A | Orally disintegrating tablet | SANWA KAGAKU KENKYUSHO CO | 2016-03-02 | — | — | CN | disclosed |
| CN-102711759-B | Therapeutic or prophylactic agent for biliary diseases | TORAY INDUSTRIES | 2015-05-13 | — | — | CN | disclosed |
| US-20130203797-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR BILIARY DISEASES | TORAY INDUSTRIES, INC. (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2529739-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR BILIARY DISEASES | Toray Industries, Inc. (JP) | 2012-12-05 | — | — | EP | disclosed |
| CN-102711759-A | Therapeutic or prophylactic agent for biliary diseases | TORAY INDUSTRIES | 2012-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203797-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR BILIARY DISEASES | SLC10A1, SLC10A2, NR1H4 | OPRM1 3366/4885OPRD1 2721/4885OPRK1 2621/4885 |
| US-20250073226-A1 | USE OF OPIOID FOR TREATMENT OF AUTISM SPECTRUM DISORDERS | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.